Ivarmacitinib, a novel Janus kinase 1 inhibitor, may be considered a potential treatment for patients with moderate to severe ...

Sareum Holdings plc (LON:SAR – Get Free Report) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 29.92 ($0.38) ...

Patients with vitiligo are often told nothing can be done, but even severe disease is potentially treatable, a recent ...

Trial data has suggested that upadacitinib, a JAK1-selective inhibitor, is more effective at treating RA than Humira. Some analysts predict sales could eventually reach $3 billion a year or more.

Deuruxolitinib, a JAK1/JAK2 inhibitor, is FDA-approved for moderate to severe alopecia areata, marking a significant advancement in treatment options. The THRIVE-AA1 trial showed deuruxolitinib's ...

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...

SDC-1801 (autoimmune disease) SDC-1801, Sareum's TYK2/JAK1 inhibitor, continues to demonstrate promising therapeutic potential for a range of autoimmune diseases with a potential initial focus on ...